Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lonafarnib
- Development stage
- Approved
- Lead developer
- Sentynl Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lonafarnib is an orally active small molecule farnesyltransferase inhibitor used to reduce the risk of death in patients with Hutchinson-Gilford progeria syndrome (HGPS) and certain processing-deficient progeroid laminopathies. It works by inhibiting farnesyltransferase, thereby preventing the farnesylation and subsequent accumulation of defective proteins such as progerin, which are implicated in premature aging disorders. Lonafarnib was originally developed for oncology indications but is now primarily indicated for rare genetic conditions causing rapid aging. The drug was discovered by Merck & Co., and further developed and brought to market by Eiger BioPharmaceuticals under the brand name Zokinvy[1][2][3][5][8].
- Brand names
- Zokinvy
- Other names
- lonafarnib
02
Targets
FTase (Protein Farnesyltransferase)RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on lonafarnib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lonafarnib.